Studies have demonstrated the ability of apo-transferrin (aTf) to induce oligodendroglial cell maturation, remyelination in animal demyelination models, and neuroprotection in humans. Therefore, studies were designed to establish a minimally invasive and controlled technique to deliver aTf to the central nervous system. Jorge Correale, MD, Raúl Carrea Institute for Neurological Research (FLENI), Buenos Aires, Argentina, discusses the use of extracellular vesicles as nanocarriers of aTf. Extracellular vesicles were isolated from mouse and human plasma, characterized and loaded with aTf through binding to Tf receptor 1. Successful loading of vesicles highlights them as potential nanovehicles to deliver aTf to the central nervous system (CNS). Further studies into their clinical application and intranasal administration are needed. This interview took place during the ACTRIMS Forum 2021.